Shandong Luoxin Pharmaceutical
Shandong
China
Tel: 0539-7086953
Fax: 0539-7086396
Website: http://www.luoxin.cn/INDEX.ASP
Email: trade@luoxin.cn
About Shandong Luoxin Pharmaceutical
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. engages in the manufacture and sale of pharmaceutical products in the People’s Republic of China. It is also involved in the manufacture and wholesale of biochemical products and Chinese medicine. The company was formerly known as Shandong Luoxin Pharmacy Stock Co., Ltd. and changed its name to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in August 2014. The company was founded in 1995 and is based in Linyi, the People’s Republic of China. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. is a subsidiary of Shandong Luoxin Holdings Co., Ltd.YEAR FOUNDED:
1995
LEADERSHIP:
CEO: Minghua Li
JOBS:
Please click here for Shandong Luoxin Pharmaceutical job opportunities.
PRODUCTS:
All Products
4 articles about Shandong Luoxin Pharmaceutical
-
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
10/21/2021
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd., signed a licensing agreement with Austria-based Marinomed Biotech AG, whereby Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® in China.
-
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
-
Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group for TRULANCE® (plecanatide) in China
8/7/2018
Synergy Pharmaceuticals Inc. announced that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing Luoxin exclusive rights to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide)
-
Shandong Luoxin Pharmaceutical Receives A Voluntary Conditional Offer
4/11/2017